A landmark peer-reviewed study published in Otology & Neurotology in August 2025 has delivered what many patient advocates and attorneys are calling the most damning scientific evidence yet against Advanced Bionics: 42.6% of HiRes Ultra V1 cochlear implants failed within seven years of implantation across four of the nation’s most respected academic medical centers. For the thousands of Americans and Canadians living with these recalled devices — and for the families who watched loved ones undergo painful revision surgeries — that number is not just a statistic. It is the foundation of an accelerating cochlear implant lawsuit wave reshaping the medical device litigation landscape in 2026.
The 2025 Study That Changed Everything: What the Data Actually Shows
Researchers at Vanderbilt University Medical Center, Mayo Clinic, UT Southwestern, and Baylor College of Medicine pooled their clinical data and published their findings in Otology & Neurotology (Vol. 46, No. 7, pp. 789–795, August 2025). The results were stark: 205 of 483 implanted HiRes Ultra V1 devices failed over a seven-year follow-up period, producing an aggregate failure rate of 42.6%. Critically, failure rates varied dramatically by institution — ranging from 32% to 67% — suggesting that the device’s failure mechanism may be exacerbated by individual patient factors, surgical variables, or regional climate conditions affecting moisture ingress.
Those findings do not stand alone. A meta-analysis of six peer-reviewed studies found a pooled failure rate of 23.7% for recalled devices, with device-specific failure at 21.5% — numbers that, taken together with the 2025 landmark study, paint a consistent picture of a defective product whose risks were known long before patients began losing their hearing again. Adding further context, FDA MAUDE database data covering 2016 through 2024 shows that cochlear implant device failure complaints declined from 27.75% in 2019 to 21.86% in 2024 — a trend that may reflect improved manufacturing protocols, but does nothing to reduce the legal exposure for patients already harmed by earlier devices.
Perhaps most significant for cochlear implant lawsuit purposes: 79% of documented device failures led to revision surgery — a procedure that carries its own serious risks, including facial nerve damage, infection, dizziness, and permanent hearing loss. Patients who underwent revision surgery did not simply receive a new device and resume normal life. Many experienced prolonged periods without hearing benefit, neurological complications, and in some cases irreversible injury to auditory structures.
A companion 2026 study published in Otolaryngology–Head and Neck Surgery (Liu et al., 2026, Vol. 174, pp. 204–209) assessed early failure risk and long-term outcome trends at Thomas Jefferson University in patients monitored after the recall. A separate April 2026 publication in Otology & Neurotology (Vol. 47, No. 4, pp. e627–e634) found survival rates of only 30.6% for adults and 33.3% for children across 105 monitored devices — numbers that underscore the systemic nature of the failure pattern, not isolated incidents. An earlier single-institution study (PMC9335892) had already identified a 21.1% known failure rate across 308 devices, with an average time-to-failure of just 2.2 years. Reinforcing that timeline, a recent peer-reviewed study concludes that Advanced Bionics cochlear implant failures primarily occur within the first five years post-implantation, with significantly reduced risk beyond that window — a finding that carries direct implications for statute of limitations analysis and the urgency facing patients who have not yet filed claims.
A Timeline of Accountability: From the 2020 Recall to Recent Settlements
Advanced Bionics did not arrive at 2026 with a clean record. In February 2020, the company issued a voluntary field corrective action recalling its HiRes Ultra and HiRes Ultra 3D cochlear implants after accumulating reports of hearing degradation and the need for revision surgeries. The identified mechanism was fluid and moisture ingress at the electrode array — a defect that caused progressive impedance abnormalities on audiological testing, followed by abrupt device shutdown and loss of all hearing benefit in affected patients.
Then, in December 2022, the U.S. Department of Justice announced a $12 million False Claims Act settlement with Advanced Bionics over allegations that the company had submitted false reimbursement claims to federal healthcare programs in connection with the defective devices. That figure grew in 2026, when Advanced Bionics agreed to pay nearly $13 million to resolve a separate False Claims Act complaint brought by a whistleblower in 2025 — bringing the company’s total federal fraud exposure to more than $25 million and signaling that regulators and relators alike view its conduct as systemic rather than incidental.
On the civil litigation front, 2026 brought a significant milestone when Advanced Bionics settled remaining negligence claims in a New York federal cochlear implant case in August 2026. U.S. Magistrate Judge Gabriel Gorenstein approved the settlement, describing it as “highly favorable to plaintiff” — language that will not be lost on plaintiffs’ counsel evaluating the strength of pending and prospective claims. Taken together, this pattern of federal settlements and favorable civil outcomes reflects a litigation environment in which Advanced Bionics has found it increasingly difficult to defend the indefensible.
Key Data at a Glance: Cochlear Implant Failure and Litigation Statistics
| Data Point | Figure | Source |
|---|---|---|
| HiRes Ultra V1 failure rate (7-year follow-up) | 42.6% | Otology & Neurotology, August 2025 |
| Pooled failure rate across 6 meta-analyzed studies | 23.7% | Peer-reviewed meta-analysis, 2026 |
| Device-specific failure rate (meta-analysis) | 21.5% | Peer-reviewed meta-analysis, 2026 |
| Failures leading to revision surgery | 79% | Otology & Neurotology, August 2025 |
| Adult device survival rate (105 monitored devices) | 30.6% | Otology & Neurotology, April 2026 |
| Pediatric device survival rate (105 monitored devices) | 33.3% | Otology & Neurotology, April 2026 |
| FDA MAUDE failure complaint rate (2019) | 27.75% | FDA MAUDE database, 2016–2024 |
| FDA MAUDE failure complaint rate (2024) | 21.86% | FDA MAUDE database, 2016–2024 |
| Average time-to-failure (single-institution study) | 2.2 years | PMC9335892 |
| DOJ False Claims Act settlement (2022) | $12 million | U.S. Department of Justice |
| Whistleblower False Claims Act resolution (2026) | ~$13 million | Federal court filing, 2026 |
Who Qualifies for a Cochlear Implant Lawsuit in 2026
Eligibility for a cochlear implant lawsuit against Advanced Bionics is not limited to patients whose devices have already failed. The legal landscape in 2026 encompasses a broader class of potential claimants, including those who experienced partial degradation, those who have been advised by their audiologist that device failure is likely, and those who underwent prophylactic explantation after the recall notice. The core eligibility criteria center on four questions:
- Did you receive a HiRes Ultra or HiRes Ultra 3D cochlear implant? The 2020 recall specifically covered these two device lines. Patients who received implants outside this product family may have claims under different legal theories but would not be covered by recall-specific litigation strategies.
- Did you experience device failure, hearing degradation, or revision surgery? Physical injury — or the documented risk of imminent injury — is the cornerstone of a personal injury claim. Patients who received recall notices but have not yet experienced symptoms may still have claims rooted in fear of harm, increased monitoring costs, or loss of device warranty protections.
- Were you implanted within the past several years? Given that recent peer-reviewed research identifies the first five years post-implantation as the highest-risk period for failure, patients implanted between 2018 and 2023 who have not yet experienced a failure event should consult with an attorney immediately. Their window of maximum legal risk — and maximum legal opportunity — may be closing.
- Is your claim within the applicable statute of limitations? This varies by state and by the date on which the patient knew or reasonably should have known of the injury. In many jurisdictions, the clock began running at the time of the 2020 recall notice or at the time of confirmed device failure — whichever is earlier. The urgency of 2026 filing deadlines cannot be overstated.
In addition to individual patients, parents of children who received recalled implants may bring claims on behalf of their minor children. Courts in several jurisdictions have held that the statute of limitations for minors does not begin to run until the child reaches the age of majority, potentially extending the filing window significantly for pediatric implant cases.
How Damages Are Calculated in Cochlear Implant Lawsuit Cases
Damages in cochlear implant lawsuits against Advanced Bionics fall into several recognized legal categories, each of which can generate substantial compensation depending on the severity of the patient’s injuries and the jurisdiction in which the case is filed.
Economic damages represent the most straightforward category and typically include: the cost of revision surgery (which can range from $50,000 to more than $100,000 when surgical fees, anesthesia, hospitalization, and post-operative audiological rehabilitation are included); the cost of temporary hearing assistive devices used during the period between failure and reimplantation; lost wages for patients whose hearing loss affected their employment; and future medical monitoring costs for patients whose devices remain in place but are at elevated risk of failure.
Non-economic damages — sometimes called pain and suffering damages — compensate for the subjective harm that cannot be reduced to a medical bill. For cochlear implant patients, these damages can be particularly compelling to juries. The experience of regaining hearing through a cochlear implant, and then losing it again to a device failure, is a distinctive and emotionally powerful form of harm. For patients who were deaf or severely hearing-impaired before implantation, the return to silence is not merely an inconvenience — it is a profound disability that affects every dimension of daily life.
Punitive damages may be available in jurisdictions that permit them where the plaintiff can demonstrate that Advanced Bionics acted with conscious disregard for patient safety. The company’s internal communications, regulatory submissions, and the False Claims Act settlements — now totaling more than $25 million — may provide the evidentiary foundation for punitive damage claims in appropriate cases.
It is worth noting that the August 2026 settlement in the New York federal case, described by Judge Gorenstein as “highly favorable to plaintiff,” suggests that Advanced Bionics has recognized the strength of individual negligence claims and is prepared to resolve them on terms that reflect the seriousness of the underlying harm. Attorneys handling cochlear implant cases in 2026 are using that settlement as a benchmark in evaluating and negotiating pending claims.
Why the Statute of Limitations Makes 2026 Urgent
The single most time-sensitive issue in cochlear implant litigation in 2026 is the statute of limitations. Most states impose a two-to-three-year filing window for personal injury claims involving defective medical devices. The starting point for that window — the legal concept known as the “discovery rule” — varies by jurisdiction, but courts have generally held that the limitations period begins when the plaintiff knew or reasonably should have known that their injury was caused by the device.
For many Advanced Bionics patients, that discovery date was February 2020, when the company issued its field corrective action and recall notice. Patients who received that notice, experienced hearing degradation, or underwent revision surgery in 2020 or 2021 may be approaching or have already passed the statute of limitations deadline in states with two-year filing windows — unless an exception applies.
The most important exceptions to be aware of in 2026 include:
- The discovery rule: If a patient did not learn that their hearing loss was attributable to device failure until a later date — for example, because their audiologist initially attributed symptoms to other causes — the limitations clock may not have started running until that later discovery.
- The minor plaintiff exception: As noted above, pediatric cases may have substantially extended filing windows in many jurisdictions.
- Fraudulent concealment: If Advanced Bionics actively concealed information about device failure risks — an argument supported by the False Claims Act settlements — some courts may toll the limitations period entirely until the concealment was discovered.
- Continuous treatment doctrine: In jurisdictions that recognize this doctrine, the limitations period may be extended where the patient was under continuous audiological care related to the implant.
The research finding that Advanced Bionics cochlear implant failures primarily occur within the first five years post-implantation cuts in two directions for statute of limitations purposes. On one hand, it suggests that patients implanted before 2021 who have not yet failed a device may be past their highest-risk window. On the other hand, it means that patients implanted between 2021 and 2023 — who are now entering or moving through that critical five-year risk period — may be facing device failure and litigation deadlines simultaneously. Those patients in particular should seek legal counsel in 2026 without delay.
Frequently Asked Questions About Cochlear Implant Lawsuits
Who is eligible to file a cochlear implant lawsuit against Advanced Bionics?
Any patient who received a HiRes Ultra or HiRes Ultra 3D cochlear implant and subsequently experienced device failure, hearing degradation, revision surgery, or documented device-related harm may be eligible to file a lawsuit against Advanced Bionics. Parents or legal guardians of minor children who received recalled implants may file on the child’s behalf. Eligibility is also fact-specific: patients who received recall notices but have not yet experienced device failure may still have viable claims based on increased monitoring costs, loss of device value, or the documented statistical risk of future failure. The best way to assess eligibility is to consult with an attorney who has experience in medical device litigation and cochlear implant cases specifically.
What medical evidence do I need to support a cochlear implant lawsuit claim?
The core medical evidence in a cochlear implant lawsuit typically includes: surgical records from the original implantation procedure confirming the device model and serial number; audiological testing records documenting the performance of the device over time, including any impedance abnormalities or declining speech perception scores; records of the recall notice and the patient’s response to it; records of any revision surgery, including operative notes, pathology reports, and post-operative care; and records of any treating audiologist’s conclusions regarding the cause of device failure. In cases where the device has not yet failed, records from the treating audiologist documenting the patient’s monitoring status and any current abnormalities will be important. An attorney handling cochlear implant cases can help identify, obtain, and organize this evidence through the formal discovery process.
How much compensation could I receive in a cochlear implant lawsuit settlement?
Settlement values in cochlear implant lawsuits vary significantly depending on the severity of the patient’s injury, the jurisdiction, and the strength of the individual case. Patients who underwent revision surgery and experienced complications — including facial nerve damage, infection, or permanent hearing loss — are likely to have higher-value claims than patients who experienced device failure without surgical complications. Economic damages alone in revision surgery cases can easily exceed $100,000 when all medical costs are accounted for. Non-economic damages for pain, suffering, and the loss of hearing in patients who had previously regained it can add substantially to that figure. The August 2026 settlement in the New York federal case, approved by Judge Gorenstein as “highly favorable to plaintiff,” indicates that Advanced Bionics has demonstrated a willingness to resolve strong individual claims on favorable terms. No attorney can guarantee a specific outcome, but the current litigation environment in 2026 is one in which well-documented claims are being taken seriously by the company and its insurers.
Is there a class action or MDL for cochlear implant lawsuits in the United States?
As of 2026, cochlear implant lawsuits against Advanced Bionics have primarily been pursued as individual personal injury cases rather than through a consolidated multidistrict litigation (MDL) or class action. This is consistent with the nature of the harm — device failure and revision surgery are highly individualized events, and damages vary significantly from patient to patient in ways that make individual litigation more appropriate than class-wide treatment for most plaintiffs. Attorneys handling these cases monitor the dockets in relevant federal and state courts for coordination opportunities, and the litigation landscape can shift quickly as new cases are filed and judicial assignments are made. Patients should consult with counsel about the current procedural posture of cochlear implant litigation at the time they seek legal advice.
Does the 2022 DOJ settlement affect my ability to bring a personal injury claim?
No. The 2022 Department of Justice settlement — and the separate nearly $13 million whistleblower False Claims Act resolution reached in 2026 — were civil fraud cases brought by the government and a private relator under the False Claims Act. They addressed Advanced Bionics’ alleged submission of false reimbursement claims to federal healthcare programs, not the company’s liability for individual patient injuries. A False Claims Act settlement does not extinguish the personal injury claims of individual patients who were harmed by defective devices. In fact, the admissions and findings associated with those settlements may serve as evidence in personal injury litigation, supporting claims that Advanced Bionics had a pattern of conduct that prioritized financial interests over patient safety. Patients should discuss the evidentiary implications of these settlements with their attorney when evaluating their individual claims.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.